Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding

Key Clinical Message Bleeding is a rare complication of direct oral anticoagulant potentially associated with high mortality rates. Biological monitoring is necessary for more than 24 h after idarucizumab antidote therapy in case of bleeding with dabigatran therapy.